ALEMBICLTDNSEAlembic Limited· PharmaceuticalsHighNeutral
Announced Tue, 12 Aug · 15:51 IST

Alembic Limited has informed the Exchange regarding Board meeting held on August 12, 2025.

Emphasis Of MatterRevenue DeclineResults View source PDF

ALEMBICLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Alembic Limited's board, at its August 12, 2025 meeting, approved unaudited consolidated and standalone financial results for Q1 FY26 (quarter ended June 30, 2025). Consolidated revenue from operations stood at Rs. 4,975 lakhs versus Rs. 5,078 lakhs in Q1 FY25, a slight decline of about 2%. Net profit after tax was Rs. 1,780 lakhs (vs Rs. 1,742 lakhs), and including share of associate (Alembic Pharmaceuticals), total profit was Rs. 6,164 lakhs (vs Rs. 5,582 lakhs), up roughly 10%. The API segment grew sharply to Rs. 1,295 lakhs from Rs. 1,072 lakhs, while the real estate segment declined. The board also appointed Mr. Udit Amin as Managing Director for 5 years effective October 1, 2025, replacing Mrs. Malika Amin, who steps down as MD & CEO on January 1, 2026 but stays on as a Non-Executive Director.

Likely market impact

Leadership transition is a key event as a long-serving MD & CEO exits and a family member takes over, which investors may read as continuity in strategy. API business is gaining momentum while real estate softness persists; overall numbers are broadly flat, with the electricity duty dispute still an unresolved overhang flagged by auditors.